Your Top 50 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Domenica Lorusso, Yang Xiang, Kosei Hasegawa, Giovanni Scambia, Manuel Leiva, Pier Anyelo Ramos-Elias and 24 more
- Rank
- 26 of 1,531
- Percentile
- top 1.7%
- Where
- The Lancet, 2024
- Citations
- 418
From the 2024 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.